All In Biotech

Drug Trial Radar · NCT05677971

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis

Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Mar 6, 2023

Primary completion

Jan 17, 2029

Study completion Dec 12, 2031

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
Collaborators
Takeda Development Center Americas, Inc.
First posted
Jan 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT protein in the liver, to get information on how the body processes fazirsiran (called pharmacokinetics), to test how well fazirsiran works compared with a placebo in improving measures of liver scarring including imaging and liver biomarkers (substances in the blood that the body normally makes and help show if liver function is improving, staying the same, or getting worse) as well as to check for side effects in participants treated with fazirsiran compared with those who received placebo. Participants will either receive fazirsiran or placebo. Liver biopsies, a way of collecting a small tissue sample from the liver, will be taken twice during this study.

Conditions

  • Alpha1-Antitrypsin Deficiency

Interventions

  • Fazirsiran InjectionDrug

    Participants will receive fazirsiran 200 mg/ml SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.

  • PlaceboOther

    Participants will receive placebo (sterile normal saline \[0.9% NaCl\]) SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction From Baseline of at Least 1 Stage of Histologic Fibrosis (METAVIR Staging) in the Centrally Read Liver Biopsy at Week 106 in AATD-LD With METAVIR Stage F2 and F3 FibrosisTime frame: Baseline, Week 106

Locations

89 sites in 19 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona · Recruiting

  • Mayo Clinic

    Phoenix, Arizona · Recruiting

  • University of Arizona Thomas D. Boyer Liver Institute

    Tucson, Arizona · Withdrawn

  • Gastroenterology & Liver Institute

    Escondido, California · Withdrawn

  • University of California San Diego, Altman Clinical and Translational Institute

    La Jolla, California · Recruiting

  • UCLA Pulmonary and Critical Care

    Los Angeles, California · Recruiting

  • Stanford University

    Palo Alto, California · Recruiting

  • University of California Benioff Children's Hospital

    San Francisco, California · Recruiting

  • Peak Gastroenterology Associates, PC

    Colorado Springs, Colorado · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Schiff Center for Liver Diseases/University of Miami

    Miami, Florida · Recruiting

  • Children's Healthcare of Atlanta

    Atlanta, Georgia · Withdrawn

  • Indiana University School of Medicine - Indianapolis

    Indianapolis, Indiana · Recruiting

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Recruiting

  • Ochsner Medical Center

    New Orleans, Louisiana · Recruiting

  • University of Maryland Medical Center

    Baltimore, Maryland · Recruiting

  • Brigham and Womens Hospital

    Boston, Massachusetts · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • University of Michigan Hospital

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Medical Center - Columbus

    Novi, Michigan · Recruiting

  • Mayo Clinic - PPDS

    Rochester, Minnesota · Recruiting

  • Cardinal Glennon Children's Hospital

    St Louis, Missouri · Recruiting

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Morgan Stanley Childrens Hospital of New York Presbyterian (CHONY) - PIN

    New York, New York · Withdrawn

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • Temple University Hospital

    Philadelphia, Pennsylvania · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Texoma Liver Center

    Denison, Texas · Recruiting

  • Baylor College of Medicine Medical Center

    Houston, Texas · Recruiting

  • The Texas Liver Institute

    San Antonio, Texas · Recruiting

  • Bon Secours St. Mary's Hospital

    Richmond, Virginia · Recruiting

  • VCU Medical Center North Hospital

    Richmond, Virginia · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Withdrawn

  • St Vincents Hospital Melbourne - PPDS

    Fitzroy, Victoria, Australia · Recruiting

  • LKH-Universitätsklinikum Graz

    Graz, Austria · Recruiting

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.